| Literature DB >> 24682076 |
Rong-Jane Chen1, Chu-Yung Chang2, Louis W Chang3, Shih-He Siao2, Yuan-Soon Ho4, Chih-Hsiung Wu5, Ning-Ping Foo6, Pinpin Lin7, Ying-Jan Wang2.
Abstract
Epidemiological studies indicate that women are at a higher risk developing lung cancer than men are. It is suggested that estrogen is one of the most important factors in lung cancer development in females. Additionally, cigarette smoke, and environmental pollutants, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), may play salient roles in female lung carcinogenesis. However, the mechanisms responsible for the interaction of these factors in the promotion of lung cancer are still poorly understood. The present study was designed to explore two ideas: first, the synergistic lung tumorigenic effects of 4-(methylnitrosamino)-1-(3-pyridyl)-butanol (NNK) combined with TCDD, 17β-estradiol (E2) or both through a long-term treatment experiment, and second, to identify early changes in the inflammatory and signaling pathways through short-term treatment experiments. The results indicate that A/J mice given E2 had strong effects in potentiating NNK-induced activation of MAPK signaling, NFκB, and COX-2 expression. In the long-term exposure model, E2 had a strong tumor promoting effect, whereas TCDD antagonized this effect in A/J mice. We conclude that treatment with NNK combined with either E2 or TCDD induces lung carcinogenesis and the promotion effects could be correlated with lung inflammation. E2 was shown to potentiate NNK-induced inflammation, cell proliferation, thereby leading to lung tumorigenesis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24682076 PMCID: PMC3969372 DOI: 10.1371/journal.pone.0093152
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Experimental design.
Female A/J mice were divided into 7 groups in which groups 1–3 were sham-operated (Sham) and groups 4–7 were ovariectomized (OVX). Mice were OVX 2 weeks before given NNK. Group 1 is the sham-operated control group in which mice were given corn oil i.p. 3 times per week until the end of the experiment. Groups 2–7 were pretreated with NNK (1 mg/0.1 ml/mouse, i.p.) at the 1st week of the experiment. Groups 3, 5, and 7 received a loading a dose of TCDD (5 µg kg/b.w./i.p.) from week 3 and the maintaining dose of TCDD (1.42 µg kg/b.w./i.p) 3 times weekly from week 4 for 3 weeks. In week 2, groups 6 and 7 were exposed to 17β-estradiol (E2, 2 µg/kg/b.w.) subcutaneously every 2 days continuously until the end of the experiments. The experiments were terminated after the 7th week as a short-term exposure model to detect the inflammatory response, and terminated at the 24th week as a long term exposure model to evaluate lung tumor formation.
Average lung and body weights of the mice in the short-term (7 wks) and long-term (24 wks) exposure models.
| NNK, E2, and TCDD effects on lung and body weight increases after treatment for 7 or 24 weeks | ||||||||
| Treatment | Mice numbers | Body weight (BW, g) | Lung weight (LW, g) | LW/BW ration (%) | ||||
| 7 wks | 24 wks | 7 wks | 24 wks | 7 wks | 24 wks | 7 wks | 24 wks | |
| Sham, Control | 4 | 36 | 16.7±2.06 | 22.7±2.94 | 0.11±0.01 | 0.14±0.02 | 0.68±0.08 | 0.61±0.07 |
| Sham, NNK | 4 | 36 | 16.8±2.63 | 22.8±2.18 | 0.09±0.01 | 0.13±0.02 | 0.59±0.09 | 0.59±0.10 |
| Sham, NNK+TCDD | 4 | 26 | 14.8±2.71 | 23.2±2.1 | 0.12±0.01 | 0.14±0.02 | 0.83±0.13 | 0.60±0.08 |
| OVX, NNK | 4 | 18 | 18.3±1.26 | 25.2±2.49 | 0.10±0.01 | 0.14±0.03 | 0.60±0.05 | 0.55±0.08 |
| OVX, NNK+TCDD | 4 | 18 | 19.0±1.63 | 25.2±1.74 | 0.10±0.01 | 0.13±0.01 | 0.55±0.09 | 0.53±0.06 |
| OVX, NNK+E2 | 4 | 18 | 20.2±2.16 | 24.2±1.93 | 0.11±0.02 | 0.13±0.02 | 0.56±0.06 | 0.53±0.08 |
| OVX, NNK+E2+TCDD | 4 | 20 | 18.6±1.95 | 25.3±2.54 | 0.12±0.01 | 0.12±0.02 | 0.66±0.06 | 0.49±0.05 |
Sham: sham-operated, OVX: ovariectomized, LW: lung weight, BW: body weight. E2: 17β-estradiol. Data are presented as the mean ± SEM.
Figure 2Examination of lung tumors on A/J mice.
Tumor pathology of lung tumors in A/J mice treated with NNK for 24 weeks. (a) Images of the lung surface indicate that NNK-treated mice lungs presented with numerous visible lesions (black circles) and (b) the histological characteristics of mouse lungs stained with H&E from control and NNK treatment groups. Arrows indicate the adenocarcinoma in the lungs (magnification, ×100).
The incidence and lung tumor multiplicity of lung tumor formation in A/J mice treated with NNK, NNK combined with TCDD, E2, or both.
| The prevalence and tumor multiplicity of lung tumor formation in female A/J mice | ||||
| Treatment | Mice numbers | Tumor bearing mice | Prevalence (%) | Tumor multiplicity |
| Sham, Control | 36 | 2 | 5.6 | 0.07±0.02 |
| Sham, NNK | 36 | 7 | 19.4 | 0.17±0.04 |
| Sham, NNK+TCDD | 26 | 9 | 34.6 | 0.25±0.03 |
| OVX, NNK | 18 | 2 | 11.1 | 0.17±0.08 |
| OVX, NNK+TCDD | 18 | 6 | 33.3 | 0.38±0.17 |
| OVX, NNK+E2 | 18 | 10 | 55.6 | 2.06±0.24 |
| OVX, NNK+TCDD+E2 | 20 | 20 | 50 | 0.55±0.04 |
* Significantly higher (p<0.05) compared to Sham, control groups.
Significantly higher (p<0.05) compared to Sham, NNK groups.
Significantly higher (p<0.05) compared to OVX, NNK groups.
Significantly higher (p<0.05) compared to OVX, NNK+TCDD groups.
Significantly higher (p<0.05) compared to OVX, NNK+E2 groups.
Tumor incidences are given as the number of animals with tumors/total number of animals at risk (%). Tumor multiplicity is the average tumor number on tumor-bearing mice. Data of lung tumor multiplicity are given as the mean ± SEM.
*significantly higher (p<0.05) compared to Sham, Control groups,
significantly higher (p<0.05) compared to OVX, NNK groups,
significantly higher (p<0.05) compared to Sham, NNK groups,
significantly higher (p<0.05) compared to OVX, NNK+TCDD groups,
significantly higher (p<0.05) compared to OVX, NNK+E2 groups.
Figure 3Inflammatory responses in A/J mice.
(a) TGF-β (left panel) and TNF-α (right panel) expression in serum by treatment groups. The results are expressed the means ± SEM (n = 3 in each group). *p<0.05 compared to sham control groups. # p<0.05 compared to short-term sham NNK groups. † p<0.05 compared to long-term OVX, N+T groups. ‡ p<0.05 compared to long-term OVX, N+E2+T groups. Short term: experiment terminated at the 7th week. Long term: experiment terminated at the 24th week. (b) Lung homogenates were used to detect the expression and activation of pIκB, IκB, cytoplasmic p65, nuclear p65, cytoplasmic p50, nuclear p50, COX-2 and GAPDH by using specific primary antibodies. (c) Immunohistochemistry for COX-2 protein in A/J mice lung tissues. Arrows indicated COX-2 positive stained bronchial epithelium (magnification, ×100). Sham: sham-operated, OVX: ovariectomized, C: control, N+T: NNK+TCDD, N+E2: NNK+E2 (17β-estradiol), N+E2+T: NNK+E2+TCDD.
Figure 4The involvement of the MAPK cascades and the PCNA expression in short-term exposure A/J mice.
(a) Lung homogenates were collected from each group of A/J mice. Expression and phosphorylation of pERK, ERK, pJNK, JNK, pp38, p38, cyclin D1, and GAPDH were analyzed by western blot analysis. (b) Immunohistochemistry was used to detect the expression of PCNA (cell proliferation marker) in lung tissues. The arrows indicated positive staining for PCNA in bronchial epithelium (magnification, ×100). Sham: sham-operated, OVX: ovariectomized, C: control, N+T: NNK+TCDD, N+E2: NNK+E2 (17β-estradiol), N+E2+T: NNK+E2+TCDD.
Figure 5The inflammatory and proliferative protein expression pattern in the long-term exposure groups.
(a) Lung homogenates were collected and analyzed for the expression of the inflammatory markers COX-2 and iNOS, proliferative marker PCNA, and MMP-9 by western blot analysis. (b) A model for the synergistic effects of NNK+E2, or NNK+TCDD on lung inflammation and tumor formation. Sham: sham-operated, OVX: ovariectomized, C: control, N+T: NNK+TCDD, N+E2: NNK+E2 (17β-estradiol), N+E2+T: NNK+E2+TCDD.